Arbivir (umifenovir) coated tablets 50 mg. №20

$4.20

Manufacturer: Ukraine

Antiviral agent that specifically suppresses influenza A and B viruses, including the highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes.

Therapeutic efficacy in influenza is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with influenza.

The drug belongs to low-toxic drugs, does not have a negative effect on the human body when used in recommended doses.

Out of stock

Category:

Description

Ingredients

active ingredient: umifenovir;

1 capsule contains umifenovir hydrochloride 100 mg;

excipients: potato starch, povidone, microcrystalline cellulose, calcium stearate, silicon dioxide colloidal capsule shell contains sunset yellow FCF (E 110), titanium dioxide (E 171), gelatin.

Dosage form

Capsules.

Basic physical and chemical properties: orange hard gelatin capsules. The contents of the capsules are a mixture containing granules and powder from white to white with a greenish-yellowish or yellowish tint. The presence of agglomerates of powder particles is allowed. It is allowed to apply the trademark of the enterprise – ZT on the capsule.

Pharmacotherapeutic group

Antiviral drugs for systemic use. Other antiviral drugs. ATX code J05A X13.

Pharmacodynamics

Arbivir (umifenovir) is an antiviral agent that specifically suppresses influenza A and B viruses, including the highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes.

Therapeutic efficacy in influenza is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with influenza.

The drug belongs to low-toxic drugs, does not have a negative effect on the human body when used in recommended doses.

Indications

Prevention and treatment of influenza A and B.

Contraindications

Hypersensitivity to the drug.

Dosage and administration

Apply to adults. Take Arbivir (umifenovir) orally before meals. A single dose is 200 mg.

For prevention:

In direct contact with patients with influenza: 200 mg 1 time per day for 10-14 days.

During the influenza epidemic: 200 mg 2 times a week for 3 weeks.

For the treatment of influenza: 200 mg 4 times a day (every 6 hours) for 5 days.

The maximum daily dose is 800 mg.

Best before date

2 years.

Storage conditions

Store in original packaging at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Package

10 capsules in a blister, 2 blisters in a box.